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Abstract
Background: Anaphylaxis management guidelines recommend the use of intramuscular adrenaline in severe reactions,
complemented by antihistamines and corticoids; secondary prevention includes allergen avoidance and provision of self-
applicable first aid drugs. Gaps between recommendations and their implementation have been reported, but only in
confined settings. Hence, we analysed nation-wide data on the management of anaphylaxis, evaluating the implementation
of guidelines.
Methods: Within the anaphylaxis registry, allergy referral centres across Germany, Austria and Switzerland provided data on
severe anaphylaxis cases. Based on patient records, details on reaction circumstances, diagnostic workup and treatment
were collected via online questionnaire. Report of anaphylaxis through emergency physicians allowed for validation of
registry data.
Results: 2114 severe anaphylaxis patients from 58 centres were included. 8% received adrenaline intravenously, 4%
intramuscularly; 50% antihistamines, and 51% corticoids. Validation data indicated moderate underreporting of first aid
drugs in the Registry. 20% received specific instructions at the time of the reaction; 81% were provided with prophylactic
first aid drugs at any time.
Conclusion: There is a distinct discrepancy between current anaphylaxis management guidelines and their implementation.
To improve patient care, a revised approach for medical education and training on the management of severe anaphylaxis
is warranted.
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Introduction
Background
Severe anaphylaxis is an acute and life-threatening IgE-
mediated hypersensitivity reaction [1,2]. A particular cause such
as insect venom, food items or drugs is traced in two out of three
cases [3]. Beyond skin and gastrointestinal symptoms, airway
constriction and circulatory collapse can be fatal.
Due to differences in recognition, diagnosis and reporting of
anaphylactic reactions [4], estimates of lifetime prevalence range
between 0.05% and 2% [5]. As with other allergic diseases, several
surveys suggest a rising incidence of anaphylaxis [6,7].
Primary prevention strategies have not been established yet,
stressing the need for defined first aid management. Different
practice parameters have been published to guide initial treatment
and secondary prevention of anaphylaxis.
Management Recommendations
International attempts have repeatedly been made to compile
available insight on the diagnosis and management of anaphylaxis
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[8], complemented through a European initiative focussing on
children [9]. On a national scale, the Resuscitation Council (from
the United Kingdom) has agreed on a widely implemented
guideline [10] giving detailed instructions on the use of emergency
drugs and other treatment options.
There is expert agreement [11] to apply adrenaline intramus-
cularly as first line treatment in all potentially life-threatening
anaphylactic reactions in the field, despite inconclusive evidence to
support this recommendation [12]. On account of tachyarrhyth-
mia side effects, intravenous application is limited to management
involving specialised health care providers such as anaesthetists or
emergency physicians.
The use of antihistamines and corticoids is subject to
controversy as an ancillary option, the latter supposed to be of
particular value in asthmatic individuals. There is no support
through controlled trials for both treatment options [13,14].
The mainstay of secondary prevention is patient education
focussing on avoidance of known or suspected allergens and early
symptom recognition. Self-injectable adrenaline devices as well as
oral antihistamines and corticoids are commonly provided to the
patient [15].
Besides the lack of data supporting management recommenda-
tions, their use has been only sporadically evaluated.
Current Implementation
A recent systematic review on studies reporting gaps in
anaphylaxis management traced a profound discrepancy between
guidelines and their implementation in a widespread variety of
settings [16]. Lack of knowledge about diagnosis and treatment
was identified to hamper correct management on a professional
level, leading to infrequent and delayed use of intramuscular
adrenaline and failure to prescribe auto-injectors. Patient instruc-
tion on avoidance and proper self-application of first aid drugs was
often reported to be insufficient. However, studies on anaphylaxis
management generally focussed on a subset of treatment options
(e.g. adrenaline) and rely on unique settings such as emergency
departments or schools only.
Anaphylaxis Registry
Hence, to provide sound figures for the current implementation
of guidelines, we present the first large-scale analysis of initial
treatment and secondary prevention data including all ages and
settings, from the transnational anaphylaxis registry, covering the
general population of Germany, Austria and Switzerland [17].
This will enable us to spot gaps and target interventional strategies
and to improve patient care in severe anaphylaxis.
Methods
Design and Subjects
The anaphylaxis registry consecutively recorded incident cases
of severe anaphylaxis, first occurrence and recurrent disease. It
was aimed to obtain well defined, standardized data of affected
patients in Germany, Austria and Switzerland.
Following an acute reaction, patients are being referred to
specialized outpatient clinics for further allergological evaluation,
usually related to dermatology or paediatric departments of
tertiary hospitals. 83 centres participating in the anaphylaxis
registry were included in this analysis. At these visits, all individuals
reporting respiratory or circulatory symptoms in conjunction with
the initial reaction, indicating severe anaphylaxis, were invited to
participate and asked to give written informed consent, for
children by a guardian.
The study was approved by the ethics committee at Charite´
University Medical Centre Berlin, Germany.
Measurement
All information was retrieved from patient records, and if
available complemented by emergency physicians’ protocol. Data
was acquired anonymously, and entered by trained health
professionals in allergy centres into an online questionnaire
covering symptoms, diagnostic workup, cause, co-morbidities,
and treatment details.
Since speculation about the cause of anaphylaxis is known to be
misleading, causes were limited to confirmed cases of insect sting,
food or drugs only. Grading of severity was based on symptoms
recorded, categorized according to [1]. Information on the person
having carried out first aid treatment was pooled in 5 clusters to
reflect assumed level of training in emergency handling, profes-
sionals in 3 (emergency, hospital or registered physicians) and lay
helpers in 2 (first aid drugs lay- or self-administered).
Quality Management
At time of inclusion, centres received training to assure quality
standards. An independent expert committee updated the
questionnaire annually, based on e.g. double entry congruency.
To account for heterogeneity of anaphylactic reactions, closed
questions were complemented by free text manually.
Representativeness and accuracy of the anaphylaxis registry
were assured through data collected directly from emergency
physicians (EPs) in a sample catchment area. EPs were asked to
complete a condensed version of the original questionnaire used
for the Registry immediately after first aid treatment.
Analysis
Independent evaluation was performed by two trained epide-
miologists, using SAS 9.2 (SAS Institute Inc., Cary, U.S.). The
cross-sectional information in the Registry allowed for the
calculation of frequencies (of categories) only. Basic stratification
was used to identify subgroup differences. Confidence intervals of
prevalence measures were calculated using the standard Wald
procedure. Weighting of EPs’ validation data was performed using
a logistic regression model including age, cause and severity to
match distribution of cases in anaphylaxis registry, Berlin
catchment area. Missing data was minimized by individual queries
involving the referral centres, if unavailable analyses were
restricted to complete cases.
Results
Of 83 referral centres participating in the anaphylaxis registry,
58 entered valid data between 2006 and 2010, 27 centres on 10 or
more patients (17 dermatology, 9 paediatrics, 1 other). 2114
patients sought further evaluation of severe anaphylaxis, more
than 85% within 6 months after the incident. In accord with
population sizes, distribution of country membership (Germany
75.8%, Austria 9.1%, Switzerland 15.1%) and sex (female 47.2%)
was well-balanced, with about one-fifth below legal age (20.2%).
The most common assured cause of anaphylaxis was insect sting
(47.9%), followed by food (16.0%) and drugs (9.4%, table 1).
First aid Treatment
One in three reactions were initially handled by an emergency
physician (EP, 34.5%), 37.6% by other physicians, and 10.0%
received first aid treatment through non-professionals (self- or lay-
administered). However, Switzerland reported a lower frequency
of EP treatment (14.7%) and a higher for lay-administered drugs
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(12.5%). Children and adolescents were also more likely to receive
first aid treatment by lay helpers (18.7 vs. 1.9% in adults),
especially at pre-school age (33.2%).
Of all anaphylactic reactions taking place in a hospital or
medical practice (n = 224), 61.3% were caused by drugs and were
most commonly treated by physicians on site (79.1%). Food items
were responsible for 77.5% of severe anaphylaxis cases in
restaurants (n = 84), and more often treated with self-administered
first aid drugs than in other reactions (10.2 vs. 4.5%).
Severest cases with respiratory and/or circulatory arrest (n = 64)
were more often treated by EPs (59.4 vs. 33.5%).
Recurrent disease accounted for 32.2% of registered reactions.
Among these, first aid drugs were more commonly self- (13.1 vs.
1.6%) or lay-administered (8.5 vs 2.9%) compared to first
occurrence cases.
First Aid Drugs
13.0% received adrenaline, irrespective of the cause. Applica-
tion of antihistamines (50.1%) and corticoids (51.3%) was both less
frequent in insect venom reactions compared to other elicitors.
Beta-2-agonists were mainly given in food-induced anaphylaxis
(5.9% in all reactions). Treatment with oxygen (6.3%) and fluids
(13.9%) was more common in drug reactions than in insect venom
or food-induced anaphylaxis (figure 1).
Application Routes
Adrenaline was applied mainly intravenously (7.6%), compared
to the recommended intramuscular route (3.9%), especially in
Austria (18.7 vs. 3.1%). Only centres from Switzerland reported a
frequent use of the intramuscular route (6.9%). EPs were more
likely to apply adrenaline intravenously (11.9%), where self- and
lay-administration was mainly intramuscular (23.2% and 12.6%).
Less than half cases suffering respiratory and/or circulatory arrest
received adrenaline (48.0%, table 2). With a steady age
distribution for all application routes, adrenaline per inhalation
was confined to the first 2 decades of life and decreased thereafter
(figure 2).
Antihistamines and corticoids were given intravenously in most
cases receiving that agent (38.1% and 42.9%), oral application was
common in non-professional first aid treatment (table 2). Overall
use of antihistamines and corticoids was highest in childhood and
adolescence, mainly due to a high proportion of oral application,
which declined in higher age groups (figure 2).
Inhalation of beta-2-agonists was confined to less severe
reactions and most frequently lay-administered (22.5%).
Compared to other countries report of oxygen and fluid therapy
was highest in Austria (11.4/32.6%). Only 29.7 and 31.3% of the
most severe reactions (uIV) received oxygen and fluids (table 2).
Validation Data
To account for reporting error in the anaphylaxis registry, we
collected firsthand information on treatment of 218 severe
anaphylaxis cases from EPs in the catchment area Berlin,
Germany. Baseline characteristics were similarly distributed,
except for an underrepresentation of females in the Anaphylaxis
Registry (59.8 vs. 28.9%). Besides a lower frequency of drug-
related anaphylaxis (18.8 vs. 7.8%) occurring mainly in hospitals
(13.1 vs. 3.2%), reaction circumstances such as location, cause and
severity recorded in the anaphylaxis registry resemble EP’s
firsthand data (table 3).
Frequency of adrenaline administered parenterally was lower in
the registry compared to Berlin EPs’ direct report, even after
accounting for differences in baseline characteristics and reaction
circumstances. Comparison of antihistamines and corticoids
indicated a similar proportion of underreporting in the anaphy-
laxis registry. Failure to trace non-drug treatments became
apparent matching data on oxygen and fluid therapy (figure 3).
Instruction and Immunotherapy
61.5% of all cases were given general advice on anaphylaxis,
including avoidance recommendation and delivery of allergy IDs.
Figure 1. Drugs used for emergency treatment of anaphylaxis, by cause. Only assured cases. All application routes, error bars indicate 95%
confidence intervals.
doi:10.1371/journal.pone.0035778.g001
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75.1% received information on the use of first aid drugs in case of
recurrent disease. Only a small proportion was instructed at the
time of the initial reaction (11.6 and 19.6% respectively).
Children and adolescents were more likely to receive instruc-
tions (78.2/86.5%). Furthermore, cases of food-induced anaphy-
laxis were commonly given general and specific information on
first aid drugs immediately following the incident (21.0/27.7%).
68.2/57.7% of patients with the most severe reactions (uIV) were
instructed at any time (table 4).
Figure 2. Drugs used for emergency treatment of anaphylaxis, by age. Dashed lines indicate proportion of patients having received
inhalation (adrenaline) or oral (antihistamine, corticoid) treatment only, error bars indicate 95% confidence intervals.
doi:10.1371/journal.pone.0035778.g002
Table 2. Application routes of drugs used for emergency treatment, stratified by country, first aid treatment and severity.
Adrenaline Antihistamine Corticoid
Beta-2-
Agonist Oxygen Fluid
IM IV inhal. IV PO IV PO inhal.
n % % % % % % % % % %
Total 2114 3.9 7.6 2.3 38.1 13.8 42.9 8.7 5.9 6.3 13.9
Country
Germany 1602 3.4 6.4 1.9 34.9 11.0 40.8 6.1 5.5 5.7 12.2
Austria 193 3.1 18.7 2.6 54.4 6.7 58.5 2.6 3.6 11.4 32.6
Switzerland 319 6.9 6.6 4.1 44.2 31.7 44.2 25.4 9.1 6.3 11.0
Inital treatment by
Emergency physician 730 1.5 11.9 2.6 48.1 3.7 54.0 2.5 2.7 8.5 17.8
Physician in hospital 499 3.4 7.8 2.8 51.3 10.0 57.7 5.4 7.0 6.6 15.6
Physician in med. practice 296 4.1 8.4 2.4 43.9 14.9 50.7 9.5 9.8 8.1 19.3
Drugs lay-administered 111 12.6 1.8 3.6 15.3 72.1 18.0 40.5 22.5 5.4 9.9
Drugs self-administered 99 23.2 1.0 0.0 6.1 66.7 6.1 53.5 8.1 1.0 1.0
Severity (following [1])
Severe reaction (II) 587 4.3 2.7 2.2 38.5 19.4 43.6 12.1 10.2 3.6 6.1
Shock (III) 1448 3.9 8.0 2.1 38.0 11.9 42.5 7.5 4.4 6.4 16.4
Resp./circ. arrest (IV) 64 1.6 42.2 6.3 40.6 4.7 51.6 4.7 0.0 29.7 31.3
IM - intramuscular, IV - intravenous, PO – oral, inhal. - per inhalation.
doi:10.1371/journal.pone.0035778.t002
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43.9% underwent specific immunotherapy, with the highest
frequency in anaphylaxis caused by insect venom (82.6%).
Prophylaxis
80.8% were given prophylactic first aid drugs at any time.
Adrenaline auto-injectors were prescribed in 64.2%, oral antihis-
tamines and corticoids in 79.1/78.0%. Of those receiving any
prophylaxis, only one in five was given adrenaline and one in three
antihistamines and corticoids immediately after the anaphylactic
reaction (figure 4).
Discussion
Key Results
Severe anaphylaxis in the field was generally handled by
professionals, involvement of lay helpers was only frequent in
children and adolescents. Overall, less than 1 in 6 received
adrenaline, even worse, only half of patients with respiratory or
circulatory arrest. Though, application of antihistamines and
corticoids was reported for the majority of anaphylactic reactions.
Against current guidelines, adrenaline was applied intravenously
by health professionals of any background in many cases.
Only 1 in 5 was provided with general information and
adrenaline auto-injectors immediately after the incident, most
patients received their first instructions at the referral centre visit.
About 1 in 6 did not receive specific immunotherapy following
severe insect venom anaphylaxis.
The distinct underuse of adrenaline is in line with several prior
surveys of anaphylaxis management, for example from US
emergency departments [18] or a questionnaire-based approach
targeting German paediatricians [19]. The preference for intra-
venous application as seen in other settings (e.g. [20]) is not
supported by guidelines or original literature [21,22]. Yet, this
analysis provides the first transnational and population-based
survey of first aid treatment and secondary prevention of severe
anaphylaxis. With a general perspective we demonstrated severe
under- and misuse of adrenaline and failure to provide adequate
patient instructions in the acute setting.
Strengths and Weaknesses
All data in the anaphylaxis registry is derived from medical
records in specialized referral centres, supplemented by emer-
gency physician’s on-site documentation, if available. Transcrip-
tion from the records is carried out by trained professionals and
is shown to be accurate by double entry comparison. But
content of medical records on the other hand is non-
standardised, its integrity limited by the patient’s failure to spot
and recall treatment details. Comparison with data collected
directly from EPs fortunately revealed only a moderate
underreporting of adrenaline, antihistamine and corticoid use
in the anaphylaxis registry, not to the extent to change
Table 3. Baseline characteristics and reaction circumstances of severe anaphylaxis patients treated by emergency physicians.
Emergency Physicians Anaphylaxis Registry#
Berlin* (n=218) Berlin* (n =90) all centres (n =730)
n (%) n (%) n (%)
Sex
Female 128 (59.8) 26 (28.9) 370 (50.7)
Male 86 (40.2) 64 (71.1) 360 (49.3)
Age
,18 years 14 (6.4) 1 (1.1) 89 (12.2)
18–64 years 154 (70.6) 77 (85.6) 512 (70.1)
.64 years 50 (22.9) 12 (13.3) 129 (17.7)
Location of anaphylactic reaction
Hospital, medical practice 28 (13.1) 2 (3.2) 12 (2.2)
Work place, school 11 (5.1) 6 (9.7) 36 (6.5)
Restaurant 6 (2.8) 10 (16.1) 28 (5.1)
At home 119 (55.6) 22 (35.5) 189 (34.2)
Outdoors (nature) 9 (4.2) 10 (16.1) 185 (33.5)
Outdoors (city) 34 (15.9) 9 (14.5) 82 (14.9)
Cause (only confirmed)
Insect sting 49 (22.5) 23 (25.6) 436 (59.7)
Food 31 (14.2) 18 (20.0) 84 (11.5)
Drugs 41 (18.8) 7 (7.8) 41 (5.6)
Severity (following [1])
Severe reaction (II) 33 (15.1) 25 (27.8) 144 (19.7)
Shock (III) 176 (80.7) 60 (66.7) 539 (73.8)
Resp./circulatory arrest (IV) 9 (4.1) 5 (5.6) 38 (5.2)
Reported by emergency physicians in Berlin, Germany vs. self report in anaphylaxis registry.
*comparable catchment areas, # only those initally treated by emergency physician.
doi:10.1371/journal.pone.0035778.t003
Anaphylaxis Management
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Figure 3. Drugs used by emergency physicians for initial treatment of anaphylaxis. Firsthand report (EPs) vs. self report (anaphylaxis
registry). Parenteral application routes only. * Weighted for age, cause and severity distribution in anaphylaxis registry, Berlin catchment area.
doi:10.1371/journal.pone.0035778.g003
Table 4. Patient instruction and specific immunotherapy after severe anaphylaxis, stratified by general characteristics and reaction
circumstances.
General instructions (avoidance,
allergy ID)
Instructions for emergency
medication SIT
at initial
reaction In between
at referral
centre
at initial
reaction In between
at referral
centre
n % % % % % % %
Total 2043 11.6 7.6 51.6 19.6 14.5 54.4 43.9
Children (,18 years) 410 27.1 9.5 58.0 31.2 10.2 62.7 24.6
Country
Germany 1545 12.9 8.6 47.8 18.6 17.2 51.7 45.6
Austria 190 3.2 5.3 53.2 7.9 8.4 61.1 50.5
Switzerland 308 10.7 3.9 69.8 31.5 5.2 63.6 31.2
Type of referral centre
Dermatology 1644 7.9 7.2 49.1 17.2 15.8 53.4 48.4
Paediatrics 320 32.5 10.6 62.2 34.4 9.1 63.1 16.9
Internal medicine/ENT 78 5.1 2.6 60.3 9.0 10.3 39.7 60.3
Cause (only confirmed)
Insect sting 989 8.9 9.2 45.0 21.7 20.0 60.6 82.6
Food 328 21.0 8.8 67.1 27.7 12.2 68.3 4.0
Drugs 187 16.0 5.9 79.1 6.4 3.2 22.5 0.5
Most severe reactions (IV) 56 17.9 3.6 58.9 16.1 12.5 39.3 37.5
SIT: Specific immunotherapy, ENT: Ear, nose and throat/Otolaryngology.
doi:10.1371/journal.pone.0035778.t004
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interpretation of the data. Only the use of oxygen and fluids is
shown to be highly underreported.
To keep time and effort for the participating centres workable,
we limited the set of items covered in the database and omitted
several aspects such as dosing and timing of drugs or details of
patient education. Patients were not traced prospectively to cover
recidivism or impact of management modalities. Furthermore, our
approach is generally limited to information conveyed through the
patients, impeding statements concerning knowledge, degree of
training or attitude towards different treatment options of the initial
caregiver. For patients were identified at referral centres, this type
of registry does not allow for inferring case fatality. However, up to
date 6 deaths were reported to the registry via allergists.
Our target population comprises all individuals having experi-
enced a severe anaphylactic reaction recently, living in a
participating country. Our registry is not exhaustive as not all
patients are referred to or follow the recommendation to present to
a specialised allergy centre. Selection maybe influenced by socio-
demographic background, perceived severity of anaphylaxis or
other health-related attitudes. Furthermore, not all referral centres
were traced or included in the study, rising concern about
differential selection. Fortunately, general patient characteristics
and circumstances of anaphylaxis based on data directly collected
from EPs were comparable to our study population.
We assume to base the following interpretation on a highly
standardized and valid set of primary data drawn from a sample
representative of the general population.
Implications
In light of established guidelines for the management of
anaphylaxis, our survey confirmed known major gaps in their
implementation on a transnational scale.
Failure to apply adrenaline timely and correctly in unquestion-
able severe anaphylaxis is most striking, in the field as well as in
professional settings. In addition, only a minority of cases receive
early and thorough patient education and preventive first aid
drugs. We suppose a lack of knowledge and practical training to be
responsible for these drawbacks. Our study identified not only EPs
but all medical professionals as the target audience for continuing
education, they are accountable for more than 90% of initial
treatments, the main setting to advance management.
Recommendations
To improve treatment of anaphylaxis, we strongly recommend
revision of medical education and practical training, targeting a
broad range of professionals [23]. This approach could foster a
high coverage of guideline-conform management. We propose a
close collaboration of physicians in primary care settings such as
EPs and specialised allergists for the development of interventional
strategies. With our strong data at hand, there is no reason to delay
implementation of educational programs on a national or even
transnational scale.
The European Academy of Allergy and Clinical Immunology
(EAACI) is currently putting together an updated guideline for the
management of anaphylaxis in children and adults (personal
communication). Yet, to achieve sufficient implementation of
current and future recommendations, a new approach for the
dissemination of guidelines and continuing medical education is
inevitable.
The future role of the anaphylaxis registry, currently embracing
other European countries, is to monitor trends and evaluate
interventional strategies aiming to improve patient care and other
public health goals, concerning aspects of anaphylaxis occurrence,
natural history of disease and management [24]. Alongside these
given aims of our survey, comparison of treatment options might
prove helpful to settle the longstanding debate about the
effectiveness of first aid drugs, especially adrenaline, not yet
resolved by interventional trials.
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